RBRosario Rivera Buery

Rosario Rivera Buery

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rosario Rivera Buery has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Chong Huat Siar

    Department of Oral Pathology Oral Medicine and Periodontology Faculty of Dentistry University of Malaya Kuala Lumpur Malaysia

    1 shared publication
  • Hitoshi Nagatsuka

    Department of Oral Pathology and Medicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan

    1 shared publication
  • Kojun Setsu

    Faculty of Pharmaceutical Science Laboratories for Structure and Function Research Tokushima Bunri University Tokushima

    1 shared publication
  • Masae Fujii

    Department of Oral Pathology and Medicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan

    1 shared publication
  • Masahisa Inoue

    Faculty of Pharmaceutical Science Laboratories for Structure and Function Research Tokushima Bunri University Tokushima

    1 shared publication
  • Mathieu Lefeuvre

    Department of Oral Pathology and Medicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan

    1 shared publication

Latest Publications

  • Open Access

    NRAS and BRAF mutation frequency in primary oral mucosal melanoma

    by Rosario Rivera Buery, Chong Huat Siar, Naoki Katase, Mehmet Gunduz, Mathieu Lefeuvre, Masae Fujii, Masahisa Inoue, Kojun Setsu, Hitoshi Nagatsuka

    Oral mucosal melanoma (OMM) is a fatal sarcoma of unknown etiology. Histological morphology and genetic events are distinct from those of its cutaneous counterpart. Mutation and up-regulation of c-kit has been identified in OMM which may activate downstream molecules such as RAS and RAF. These molecules are involved in the mitogen-activated protein kinase (MAPK) pathway leading to tremendous cell proliferation and survival. NRAS and BRAF mutation and protein expression have been studied in other melanoma subtypes. The purpose of this study was to determine RAS protein expression and NRAS and BRAF mutation in 18 primary OMM cases using immunohistochemistry and mutation analysis. Results showed that RAS is intensely expressed in both in situ and invasive OMMs. However, NRAS mutation was only observed in 2/15 polymerase chain reaction (PCR) amplified cases both of which were silent mutations. On the other hand, BRAF missense mutations were observed only in 1/15 cases with PCR amplification. NRAS and BRAF mutations were independent from previously reported c-kit mutations. The classical V600E BRAF mutation was not found; instead a novel V600L was observed suggesting that the oncogenic event in OMM is different from that in skin melanoma. The low frequency of NRAS and BRAF mutations indicate that these genes are not common, but probable events in OMM pathogenesis, most likely independent of c-kit mutation.